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Abstract
The most common genetic cause of neonatal diabetes and hyperinsulinism is pa-
thogenic variants in ABCC8 and KCNJ11. These genes encode the subunits of the
β‐cell ATP‐sensitive potassium channel, a key component of the glucose‐stimulated
insulin secretion pathway. Mutations in the two genes cause dysregulated insulin
secretion; inactivating mutations cause an oversecretion of insulin, leading to con-
genital hyperinsulinism, whereas activating mutations cause the opposing pheno-
type, diabetes. This review focuses on variants identified in ABCC8 and KCNJ11, the
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phenotypic spectrum and the treatment implications for individuals with pathogenic
variants.
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1 | INTRODUCTION
ATP‐sensitive potassium (KATP) channels were found to couple glu-
cose metabolism to membrane electrical activity and insulin release
over 30 years ago (Ashcroft, Harrison, & Ashcroft, 1984; Cook &
Hales, 1984; Rorsman & Trube, 1985). This landmark discovery was
fundamental to further understanding of the insulin secretion path-
way whereby glucose metabolism results in a change in ratio of ADP
and ATP. The binding of ATP to the channel induces channel closure,
depolarization of the membrane, and activation of voltage‐dependent
F IGURE 1 Schematic representation of insulin secretion in the pancreatic β‐cell. (a) In a normal cell in a high plasma glucose environment. (b) In a cell
with an activating KATP channel mutation. (c) In a cell with an inactivating mutation resulting in the absence/reduction in protein at the membrane
surface d) In a cell with an inactivating mutation that impairs the stimulatory effect of MgADP (a) Glucose is metabolized after entry into the β‐cell via a
GLUT transporter. This results in change in the ATP:ADP ratio, leading to channel closure and membrane depolarization and activation of voltage‐
dependent calcium channels. Calcium enters the cell, which triggers insulin release. (b) An activating mutation in a KATP channel gene results in the
membrane being maintained in a hyperpolarized state. Calcium channels remain closed and insulin is not secreted. (c) Loss‐of‐function mutations can
result in an absence/reduction in protein at the membrane surface. This keeps the membrane in a depolarized state, regardless of the metabolic state
ultimately leading to unregulated insulin secretion. (d) Loss‐of‐function missense mutations can produce channels that traffic to the membrane but have
impaired mgADP activation
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calcium channels, leading to calcium influx, and insulin granule exo-
cytosis (Figure 1a).
Given the role of the KATP channel in insulin secretion, it is not
unexpected that variants in KCNJ11, encoding the four pore‐forming
inwardly rectifying Kir6.2 subunits, and ABCC8, encoding the four
sulphonylurea receptor 1 (SUR1) subunits of the channel, can cause
hypo‐ or hyperglycemia (Babenko et al., 2006; Gloyn, Pearson,
et al., 2004; Thomas et al., 1995; Thomas, Ye, & Lightner, 1996).
Identifying these mutations is important for informing prognosis,
medical management, and recurrence risk.
Over recent years, the number of variants identified in these two
genes has expanded tremendously. In 2006, 124 disease‐causing
mutations were reported, which increased to 265 pathogenic
variants 3 years later (Flanagan et al., 2009; Gloyn, Siddiqui, &
Ellard, 2006). By combining published reports together with data
from five international molecular genetic screening laboratories in
the UK, Denmark, France, and the United States of America, we now
report 953 pathogenic ABCC8 and KCNJ11 variants (Tables S1–S6)
and discuss the role of these genes in congenital hyperinsulinism
(CHI) and monogenic diabetes.
2 | CONGENITAL HYPERINSULINISM
CHI is characterized by the inappropriate secretion of insulin
despite low blood glucose, which can result in irreversible brain
damage if not promptly treated (Helleskov et al., 2017). The
condition has a variable phenotype usually presenting during
the neonatal period or infancy with seizures and/or coma and a
large birth weight due to high levels of insulin acting as a growth
factor in utero.
Although most cases of CHI are sporadic, rare familial forms
have been well documented. Sporadic CHI has an estimated in-
cidence of between 1 in 27,000 and 1 in 50,000 live births (Glaser,
Thornton, Otonkoski, & Junien, 2000; Otonkoski et al., 1999).
However, in some isolated populations or in countries with high rates
of consanguineous unions, the incidence is higher (i.e., 1 in 2,675 to
1 in 3,200; Mathew et al., 1988; Otonkoski et al., 1999).
2.1 | CHI due to KATP channel mutations
Loss‐of‐function ABCC8 mutations were first described in 1995
(Thomas et al., 1995). These mutations either prevent trafficking
of the channel to the membrane surface or are associated with
channels that reach the surface but are not fully responsive to
MgADP activation (Figure 1; Ashcroft, 2005; Nichols et al., 1996;
Taschenberger et al., 2002). The majority of ABCC8 loss‐of‐
function mutations are recessively acting with a small number of
dominant missense mutations reported that produce channels
that traffic to the membrane but have impaired mgADP
activation.
Fewer loss‐of‐function mutations have been reported in
KCNJ11 in keeping with the gene being much smaller (1173 vs.
4749 bases, respectively; Thomas et al., 1996). Similar to ABCC8,
both dominant and recessively acting KCNJ11 mutations have
been described (Pinney et al., 2013). Mutations in these two
genes together account for 36–70% of CHI cases (Kapoor
et al., 2013; Snider et al., 2013).
There exist mouse models for KATP channel CHI; however, their
inability to fully recapitulate the human phenotype means that they
have a limited value for studying specific disease mechanisms. For
example, mice generated with a deletion of ABCC8 or KCNJ11, or
the homozygous recessive KCNJ11 mutation p.(Tyr12Ter), do not
have the sustained neonatal hypoglycemia observed in humans with
homozygous null mutations. Instead the blood glucose levels
normalize in the mouse within a few days of birth with glucose
intolerance developing in later life (Hugill, Shimomura, Ashcroft,
& Cox, 2010; Miki et al., 1998; Seghers, Nakazaki, DeMayo,
Aguilar‐Bryan, & Bryan, 2000). The differences in the phenotype
between mice and humans are not fully understood, but they
highlight the need to develop human‐specific models for studying
disease mechanisms.
2.2 | Clinical management of KATP channel CHI
In 2015, the Pediatric Endocrine Society published recommendations
for the evaluation and management of persistent hypoglycemia in
neonates, infants, and children (Thornton et al., 2015). The main
treatment for CHI is the KATP channel‐opener diazoxide; however,
patients with ABCC8/KCNJ11 mutations that prevent trafficking to
the membrane do not respond to the drug as diazoxide targets the
SUR1 subunit of the KATP channel. For approximately 50% of patients
with mutations that do not prevent the channel from reaching the
membrane, diazoxide is an effective treatment (Boodhansingh
et al., 2019). For patients with diazoxide‐unresponsive CHI, second‐
line treatment with somatostatin analogs may be helpful to control
hypoglycemia; however, adverse effects on somatostatin analogs, and
likewise diazoxide, have been reported (Demirbilek et al., 2014;
Herrera et al., 2018).
The mode of inheritance of the KATP channel mutation de-
termines the pancreatic histological subtype (de Lonlay
et al., 1997; de Lonlay et al., 2002; Jack, Walker, Thomsett,
Cotterill, & Bell, 2000; Rahier et al., 1984). Inheritance of two
recessively acting or one dominant ABCC8/KCNJ11 mutation re-
sults in diffuse disease affecting the entire pancreas. Focal dis-
ease is caused by somatic loss of the maternal chromosome
11p15.5 region by uniparental disomy that unmasks a paternally
inherited KATP channel mutation at 11p15.1. These focal lesions
often appear histologically as small regions of islet adenomatosis
that develop as a result of the imbalanced expression of mater-
nally imprinted tumor suppressor genes H19 and p57Kip2, and the
increased expression of the paternally derived insulin‐like growth
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factor II gene (Craigie et al., 2018; Damaj et al., 2008; de Lonlay
et al., 1997). Rarely, giant focal lesions have been described
where virtually the whole of the pancreas is affected (Ismail
et al., 2012). Atypical mosaic disease has also been reported in a
small number of cases (Han et al., 2017; Houghton et al., 2019;
Hussain et al., 2008; Sempoux et al., 2011).
The identification of a single recessively acting KATP channel
mutation in an individual with CHI predicts focal disease with
84–97% sensitivity, with a positive predictive value up to 94%
(Mohnike et al., 2014; Snider et al., 2013). 18F‐DOPA PET/CT
scanning can identify and localize a focal lesion before surgery
(Otonkoski et al., 2006). Intraoperative ultrasound may further aid
the surgeon to perform tissue‐sparing pancreatic resection in focal
CHI, which is potentially curative (Bendix et al., 2018).
3 | DIABETES MELLITUS
Diabetes is the opposing disorder to CHI and results from hyper‐
rather than hypoglycemia. Current estimates suggest that approxi-
mately 0.4% of all diabetes (and up to 3.5% of those diagnosed under
30 years of age) has a monogenic cause (Shepherd et al., 2016;
Shields et al., 2017). Individuals diagnosed with monogenic diabetes
outside of infancy are generally classified as having maturity onset
diabetes of the young, whereas neonatal diabetes (NDM) describes
congenital diabetes. In individuals with NDM, impaired insulin se-
cretion results in a low birth weight and hyperglycemia diagnosed
before the age of 6 months (Hattersley & Ashcroft, 2005). The
minimal incidence of NDM has been calculated to be between 1 in
89,000 and 1 in 160,949 live births (Grulich‐Henn et al., 2010;
Wiedemann et al., 2010).
3.1 | Later‐onset diabetes due to KATP channel
mutations
Dominantly acting mutations in the KATP channel genes have been
rarely described in individuals with later‐onset diabetes in the ab-
sence of documented hyper‐ or hypoglycemia in the neonatal period
(Bowman et al., 2012; Hartemann‐Heurtier et al., 2009; Huopio
et al., 2003; Koufakis et al., 2019; Tarasov et al., 2008). The me-
chanism(s) leading to this variable penetrance are not fully under-
stood and may differ according to whether the mutation is causing a
gain or loss of channel function. Interestingly, in one study, the
generation of a mouse model harboring a homozygous dominantly
acting loss‐of‐function ABCC8 mutation p.(Glu1507Lys) recapitulated
the biphasic phenotype with the mice having increased insulin se-
cretion in early life and reduced insulin secretion later on. This was
shown to be resulting from a reduction in insulin content rather than
a reduction of islet number and/or size. Heterozygosity for the
mutation did, however, not result in a phenotype in the mouse,
further highlighting differences between the mouse models and
human disease (Shimomura et al., 2013).
3.2 | Neonatal diabetes due to KATP channel
mutations
Strong support for the role of gain‐of‐function KATP channel muta-
tions in the etiology of diabetes came from the observation that mice
overexpressing a mutant KATP channel with reduced ATP sensitivity
developed diabetes within 2 days (Koster, Marshall, Ensor, Corbett, &
Nichols, 2000). In 2004, the first heterozygous activating KCNJ11
mutations causing NDM were described in humans with activating
ABCC8mutations reported 2 years later (Babenko et al., 2006; Gloyn,
Pearson, et al., 2004; Proks et al., 2006). Mutations in these two
genes together have now been shown to account for approximately
40% of NDM cases (De Franco et al., 2015; Stoy et al., 2008).
Both dominant and recessive activating mutations are frequently
identified in ABCC8. Conversely for KCNJ11, all, but one of the mu-
tations reported so far, p.(Gly324Arg), have been dominantly acting.
The majority (~60%) of dominant mutations arise “de novo,” so there
is often no family history of diabetes; however, germline mosaicism
has been observed in some families (Edghill et al., 2007; Gloyn,
Cummings, et al., 2004).
There is added complexity associated with ABCC8 mutations, as
compound heterozygosity for both an activating and an inactivating
mutation can cause diabetes (Ellard et al., 2007). Furthermore, a
recessively inherited ABCC8 nonsense variant has been reported in
two cases with NDM, which leads to the deletion of the in‐frame
exon 17 likely resulting in enhanced sensitivity of the channel to
intracellular MgADP/ATP (Flanagan et al., 2017).
The specific KATP channel mutation identified determines
whether the diabetes will cause permanent or transient NDM (Gloyn,
Reimann, et al., 2005; Patch, Flanagan, Boustred, Hattersley, &
Ellard, 2007). Variable penetrance within families with mutations
leading to transient diabetes is observed with some individuals being
diagnosed with diabetes at birth, yet others developing diabetes for
the first time in adulthood (see previous section on adult‐onset dia-
betes; Flanagan, Edghill, Gloyn, Ellard, & Hattersley, 2006).
3.3 | Spectrum of central nervous system features
in KATP channel NDM
Central nervous system (CNS) features are frequently reported in
individuals with KATP channel NDM due to the Kir6.2 and SUR1
proteins being expressed in the brain (Karschin, Ecke, Ashcroft, &
Karschin, 1997; Liss, Bruns, & Roeper, 1999; Sakura, Ammala, Smith,
Gribble, & Ashcroft, 1995; Schmahmann & Sherman, 1998). The most
severe neurological phenotype is termed as developmental delay,
epilepsy and neonatal diabetes (DEND) syndrome, which includes
muscle weakness and hypotonia (Hattersley & Ashcroft, 2005). In-
termediate DEND (iDEND) syndrome is diagnosed when epilepsy is
absent or presents after the age of 12 months (Gloyn, Diatloff,
et al. 2006). Clinical studies have reported CNS features in ap-
proximately 20–30% of individuals with KATP channel permanent
NDM (De Franco et al., 2015; Massa et al., 2005; Sagen et al., 2004).
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Since these initial reports, studies on larger cohorts of individuals
affected with KATP channel NDM have characterized the neurological
features in more detail. Additional features reported include autism
and attention deficit hyperactivity disorder (ADHD), anxiety and
sleep disorders, dyspraxia, and learning difficulties, resulting in im-
paired attention, memory, visuospatial abilities, and executive func-
tion (Beltrand et al., 2015; Bowman et al., 2016; Bowman et al., 2017;
Bowman, Day, et al., 2018; Busiah et al., 2013; Landmeier, Lanning,
Carmody, Greeley, & Msall, 2017). More important, it is now re-
cognized that some degree of impairment can be detected on neu-
ropsychological testing in the majority of patients with KATP channel
mutations, even if there is no obvious CNS involvement (Busiah
et al., 2013; Carmody et al., 2016).
3.4 | Clinical management of neonatal diabetes and
CNS features due to KATP channel mutations
The identification of a KATP channel mutation can have an impact on
the medical management of patients with NDM as approximately
90% can transfer from insulin injections to high‐dose sulphonylurea
tablets (Pearson et al., 2006; Zung, Glaser, Nimri, & Zadik, 2004).
Sulphonylureas bind to the SUR1 subunit of the KATP channel and
close it independently of ATP, resulting in excellent long‐term gly-
cemic control and improved quality of life for affected patients and
their families (Babenko et al., 2006; Bowman, Sulen et al., 2018; Rafiq
et al., 2008). Patients who are unable to transfer to sulphonylureas
tend to have a longer duration of diabetes before attempting transfer
or functionally severe mutations (Babiker et al., 2016; Thurber
et al., 2015). Few side effects and no episodes of severe hypoglyce-
mia involving seizures or loss of consciousness have been reported
in individuals with sulphonylurea‐treated neonatal diabetes
(Bowman, Sulen, et al., 2018; Codner, Flanagan, Ellard, Garcia, &
Hattersley, 2005; Kumaraguru et al., 2009; Lanning et al., 2018).
Sulphonylureas can improve the neurological features in people with
KATP channel NDM, particularly in the first year of treatment (Beltrand
et al., 2015; Fendler et al., 2013; Stoy et al., 2008). However, these
features do not fully resolve after sulphonylurea therapy and persist for a
long term into adulthood (Bowman, Day et al., 2018; Bowmen, Sulen,
et al., 2018). Higher doses of sulphonylureas are recommended for pa-
tients with severe neurological features in an attempt to mitigate this
(https://www.diabetesgenes.org/). In addition, starting sulphonylurea
therapy as early as possible after a genetic diagnosis is crucial as the
largest improvements appear to occur in younger patients (Beltrand
et al., 2015; Shah, Spruyt, Kragie, Greeley, & Msall, 2012).
4 | GENETIC VARIATION IN ABCC8 AND
KCNJ11
KCNJ11 (MIM# 600937) is located 4.5Kb from ABCC8 on
chromosome 11p15.1 and has a single exon encoding for the
390‐amino acid Kir6.2 protein (GenBank NM_000525.3). ABCC8
consists of 39 exons that encode for the 1,582 amino acids of
SUR1 (NM_001287174.1; MIM# 600509). This gene has an alter-
natively spliced recognition site at the 5′ end of exon 17, which
results in two different transcripts differing in length by a single
amino acid (GenBank AH003589.2). This alternative splicing has
led to discrepancies in the literature for nomenclature of variants
present in 17–39, which differ by a single amino acid depending on
the isoform used (1581 amino acids, NM_000249.3 and 1582
amino acids, NM_001287174.1). For the purpose of this review, we
have described ABCC8 variants according to the longer isoform
(NM_001287174.1).
4.1 | Disease‐causing variants
A total of 748 ABCC8 and 205 KCNJ11 pathogenic or likely patho-
genic variants have been identified in individuals with CHI or NDM
(Table 1 and Table 3 and Tables S1 and S4) — please note that these
tables are meant to direct to the appropriate references and la-
boratories. They do not provide in‐depth clinical information and
variants that had been previously reported as pathogenic with a
GnomAD frequency compatible with the disease frequency (as
calculated by http://cardiodb.org/allelefrequencyapp/ using a biallelic
mode of inheritance, a prevalence of 1/50,000, an allelic hetero-
geneity of 0.1, genetic heterogeneity of 0.5, and penetrance of 0.5)
were not re‐assessed.
Founder mutations have been identified in many populations
with the best recognized example being the ABCC8 p.(Phe1388del)
and c.3992‐9G>A mutations present in >90% of cases from the
Ashkenazi Jewish population (Nestorowicz et al., 1996; Otonkoski
et al., 1999). In the Irish population, a deep intronic ABCC8 founder
mutation at position c.1333‐1013G>A has been described that gen-
erates a cryptic splice site and causes pseudoexon activation
(Flanagan et al., 2013). Founder mutations have also been reported in
Hispanic (Aguilar‐Bryan & Bryan, 1999), Bedouin (Tornovsky
et al., 2004), Spanish (Fernandez‐Marmiesse et al., 2006), Finnish
(Otonkoski et al., 1999), and Turkish populations (Flanagan
et al., 2013).
4.2 | Common variation in ABCC8 and KCNJ11
Three hundred and sixty‐eight benign/likely benign variants and
variants of uncertain significance have been observed in both genes
(Tables 2‐4, S2, S3, S5, and S6). Two common variants in linkage
disequilibrium, p.(Glu23Lys) in KCNJ11 and p.(Ser1370Ala) in ABCC8,
predispose to type 2 diabetes (Florez et al., 2004). Although their
effect size is small (odds ratio ~1.2), given that 58% of the population
carry at least one lysine allele at residue 23 in KCNJ11, this equates
to a sizeable population risk (Gloyn, Weedon, et al., 2003; Nielsen
et al., 2003).
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TABLE 1 Unpublished pathogenic variants identified in KCNJ11 (NM_000525.3)







p.(Arg4Cys) c.10C>T Missense TNDM
PNDM
Heterozygous Dominant 0.00002150 Exeter
p.(Leu17Pro) c.50T>C Missense PNDM Heterozygousdenovo Dominant 0 Exeter
p.(Tyr26Ter) c.78C>A Nonsense HI Homozygous Recessive 0 Exeter
p.(Arg27Cys) c.79C>T Missense HI HeterozygousPat Recessive 0.000007976 Chicago
p.(Lys38Glu) c.112A>G Missense HI Homozygous Recessive 0 Exeter
p.(Gly40Ala) c.119G>C Missense HI Homozygous Recessive 0 Exeter
p.(Ile49Phe) c.145A>T Missense TNDM Heterozygousdenovo Dominant 0 Exeter
p.(Glu51Gly) c.152A>G Missense PNDM Heterozygousdenovo Dominant 0 Exeter









p.(Leu56Gly) c.166_167delinsGG Missense HI Homozygous Recessive 0 Exeter
p.(Thr62SerfsTer68) c.185del Frameshift HI Homozygous Recessive 0 Exeter
p.(Cys81AlafsTer49) c.240del Frameshift HI HeterozygousPat Recessive 0 Exeter
p.(Asp99Tyr) c.295G>T Missense HI Heterozygousdenovo Dominant 0 Paris
p.(Ala120CysfsTer7) c.356dup Frameshift HI Homozygous Recessive 0 Exeter
p.(Val129Met) c.385G>A Missense NDM Heterozygousdenovo Dominant 0 Exeter
p.(Gly132TyrfsTer10) c.390_393dup Frameshift HI Homozygous Recessive 0 Exeter
p.(Cys166Trp) c.498C>G Missense NDM Heterozygous Not known 0 Chicago
p.(Met169Thr) c.506T>C Missense PNDM Heterozygousdenovo Dominant 0 Exeter
p.(Ala178LeufsTer11) c.532del Frameshift HI HeterozygousPat Recessive 0 Exeter
p.(Glu179Lys) c.535G>A Missense TNDM Heterozygousdenovo Dominant 0 Exeter










p.(Ser208Thr) c.623G>C Missense HI Heterozygousdenovo Dominant 0 Exeter
p.(Tyr258Ter) c.774C>A Nonsense HI HeterozygousPat Recessive 0 Exeter
p.(His259MetfsTer61) c.775del Missense HI Homozygous Recessive 0 Exeter
p.(Gln279Ter) c.835C>T Nonsense HI Homozygous Recessive 0 Exeter
p.(Gln289Ala) c.866G>C Missense HI HeterozygousPat Recessive 0 Chicago
p.(Gly295Ser) c.883G>A Missense HI Homozygous Recessive 0 Paris
p.(Val328Met) c.982G>A Missense TNDM Heterozygous Dominant 0 Exeter
p.(Tyr330Asn) c.988T>A Missense TNDM Heterozygous Dominant 0 Exeter
p.(Tyr330His) c.988T>C Missense Diabetes Heterozygous Not known 0 Chicago
p.(Ser331Pro) c.991T>C Missense PNDM Heterozygousdenovo Dominant 0 Exeter
p.(Gly334Ser) c.1000G>A Missense PNDM Heterozygous Dominant 0 Exeter
p.(Gly334Arg) c.1000G>C Missense PNDM Heterozygousdenovo Dominant 0 Exeter
Note: The phenotype column highlights a new phenotype; the reporting laboratory column indicates which laboratory has identified the variant in a
patient with the new phenotype. See Supporting Information data for details of inclusion criteria for variants in this table.
Abbreviations: HI, hyperinsulinism; PNDM, permanent neonatal diabetes mellitus; Ter, termination codon; TNDM, transient neonatal diabetes mellitus.
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TABLE 2 Unpublished variants of uncertain clinical significance identified in KCNJ11 (NM_000525.3)
Protein change Nucleotide position Mutation type Phenotype Zygosity Inheritance GnomAD MAF
Reporting
laboratory
p.(Arg4His) c.11G>A Missense HI Heterozygous Unaffected mother 0.000008066 Exeter
p.(Cys42Tyr) c.125G>A Missense Diabetes Heterozygous Not known 0 Paris
p.(Ala45Ser) c.133G>T Missense Diabetes Heterozygous Unaffected parent 0 Exeter











p.(Gln52Pro) c.155A>C Missense NDM Heterozygous Not known 0 Exeter
p.(Asp58Val) c.173A>T Missense HI Heterozygous Unaffected father 0 Paris
p.(Phe60Ser) c.179T>C Missense HI Heterozygous
(in cis with VUS)
Unaffected mother 0 Chicago
p.(Leu84Arg) c.251T>G Missense HI Homozygous Bi‐parental 0 Exeter
p.(Ala96Val) c.287C>T Missense HI Heterozygous Unaffected father 0 Exeter
p.(His97Tyr) c.289C>T Missense Diabetes Heterozygous Unaffected parent 0 Exeter
p.(Ile114Thr) c.341T>C Missense Diabetes Heterozygous Not known 0 Paris
p.(His115Leu) c.344A>T Missense HI Heterozygous Unaffected father 0 Paris






p.(Phe121Ser) c.362T>C Missense HI Heterozygous Unaffected father 0 Paris
p.(Ile131dup) c.391_393dup In‐Frame
duplication
HI Homozygous Bi‐parental 0 Paris
p.(Ile131Val) c.391A>G Missense HI Heterozygous Unaffected father 0 Exeter
p.(Thr139Pro) c.415A>C Missense HI Heterozygous
(in cis with VUS)
Unaffected father 0 Paris
p.(Glu140Lys) c.418G>A Missense HI Homozygous Bi‐parental 0 Paris
p.(Cys142Tyr) c.425G>A Missense HI Heterozygous Unaffected father 0 Exeter
p.(Val155Leu) c.463G>T Missense HI Heterozygous Unaffected mother 0 Exeter






p.(Leu157Val) c.469C>G Missense HI Heterozygous Unaffected mother 0 Exeter
p.(Asn160Lys) c.480C>G Missense HI Heterozygous Not known 0 Paris
p.(Ile167Val) c.499A>G Missense HI Heterozygous
(in cis with VUS)
Unaffected father 0 Paris
p.(Thr171Asn) c.512C>A Missense HI Heterozygous Unaffected father 0 Exeter
p.(Thr180Ile) c.539C>T Missense HI Heterozygous Unaffected father 0 Paris
p.(Ser208Asn) c.623G>A Missense Diabetes Heterozygous Not known 0 Paris
p.(Lys222Gln) c.664A>C Missense HI Heterozygous Unaffected mother 0.00001064 Exeter
p.(Ser265Ile) c.794G>T Missense HI Heterozygous Unaffected father 0.000003978 Exeter
p.(Tyr268His) c.802T>C Missense HI Heterozygous Unaffected father 0 Exeter
p.(Asp274His) c.820G>C Missense HI Heterozygous Unaffected father 0 Exeter
p.(Leu287Pro) c.860T>C Missense HI Heterozygous Unaffected father 0 Paris
p.(Thr297Asn) c.890C>A Missense NDM Heterozygous Unaffected parent 0 Exeter
p.(Ala300Asp) c.899C>A Missense HI Heterozygous Not known 0 Paris
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4.3 | Variant interpretation
Given the highly polymorphic nature of ABCC8 and KCNJ11, the
occurrence of both activating and inactivating mutations, the multi-
ple modes of inheritance of disease, and the variable penetrance
associated with dominantly acting mutations, interpreting variants
identified in these genes can be extremely challenging. Although the
identification of a null ABCC8 or KCNJ11 variant(s) in an individual
with CHI provides strong evidence for pathogenicity, finding a mis-
sense variant is insufficient to assign disease causality and, as such,
additional support is required to achieve a “pathogenic” classification
according to the guidelines set out by the American College of
Medical Genetics (Richards et al., 2015).
Large variant databases such as GnomAD and LOVD are pow-
erful tools that aid in variant interpretation and allow for re-
classification of variants (Fokkema et al., 2011; Lek et al., 2016). As
such, some variants previously reported as pathogenic in the litera-
ture have now been found to be too common to be causative of
disease and have now be reassigned as a variant of uncertain sig-
nificance or a benign variant (Tables S2, S3, S5, and S6).
5 | FUTURE PROSPECTS
Although sulphonylureas provide a safe and effective treatment for
the majority of individuals with KATP channel NDM, for patients with
CHI, pharmacological management of the condition is not always
successful. Current efforts are, therefore, focusing on the develop-
ment of new pharmacological treatments for this condition (Banerjee,
De Leon, & Dunne, 2017; De Leon et al., 2008; Ng, Tang, Seeholzer,
Zou, & De Leon, 2018; Patel et al., 2018; Powell et al., 2011;
Senniappan et al., 2014).
Progress is also being made in terms of genetic screening, with a
recent report describing the use of noninvasive prenatal testing of a
paternally inherited KCNJ11 activating mutation in cell‐free fetal
DNA (De Franco et al., 2017). Implementation of noninvasive pre-
natal testing for maternally inherited mutations will be extremely
important, as a previous study suggested that sulphonylurea can
cross the placenta and influence fetal growth with implications
for treatment of monogenic diabetes pregnancies (Myngheer
et al., 2014; Shepherd, Brook, Chakera, & Hattersley, 2017).
6 | SUMMARY
The discovery of both inactivating and activating KATP channel mu-
tations has firmly established the critical role of the channel in insulin
secretion. The highly polymorphic nature of the two genes along with
the occurrence of both gain‐of‐function and loss‐of‐function muta-
tions as well as multiple different modes of inheritance can make
variant interpretation extremely challenging. Rapid testing is abso-
lutely crucial for all patients with CHI or NDM because finding a
mutation has a huge impact on the clinical management of these
conditions.
TABLE 2 (Continued)
Protein change Nucleotide position Mutation type Phenotype Zygosity Inheritance GnomAD MAF
Reporting
laboratory
p.(Leu310Pro) c.929T>C Missense HI Heterozygous Not maternal 0 Exeter





p.(Arg325Ser) c.973C>A Missense HI Heterozygous
(in cis with VUS)
Unaffected mother 0.00001591 Chicago
p.(Arg325His) c.974G>A Missense HI Heterozygous Unaffected father 0.00001591 Exeter
p.(Thr336Ala) c.1006A>G Missense Diabetes Heterozygous Not known 0 Exeter
p.(Leu343Val) c.1027C>G Missense NDM Heterozygous Unaffected parent 0 Exeter
p.(Arg369Ser) c.1105C>A Missense Diabetes Heterozygous Not known 0.00003988 Paris
p.(Arg369His) c.1106G>A Missense Diabetes Heterozygous Unaffected parent 0.000003989 Exeter
p.(Arg369Leu) c.1106G>T Missense HI Heterozygous Paternal 0.000003989 Chicago





Diabetes Heterozygous Not known 0.00007098 Paris
Note: The phenotype column highlights a new phenotype; the reporting laboratory column indicates which laboratory has identified the variant in a
patient with the new phenotype. See Supporting Information data for details of inclusion criteria for variants in this table.
Abbreviations: HI, hyperinsulinism; NDM, neonatal diabetes.
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TABLE 4 Unpublished variants of uncertain clinical significance identified in ABCC8 (NM_001287174.1)
Protein change
Nucleotide
position Position Mutation type Phenotype Zygosity Inheritance GnomAD MAF
Reporting
laboratory
p.(Ala14Ser) c.40G>T Exon 1 Missense Diabetes Heterozygous Not known 0 Paris
p.(Tyr15Phe) c.44A>T Exon 1 Missense HI Heterozygous Not known 0 Paris
p.(Phe41Leu) c.121T>C Exon 1 Missense Diabetes Heterozygous Not known 0 Paris
p.(His59Asn) c.175C>A Exon 2 Missense HI Homozygous Bi‐parental 0 Paris
p.(Gly97=) c.291G>T Exon 3 Missense Diabetes Heterozygous Not known 0 Paris
p.(Val121Met) c.361G>A Exon 3 Missense Diabetes Heterozygous Affected
parent
0 Paris
p.(Val121Ala) c.362T>C Exon 3 Missense NDM Heterozygous Not known 0 Chicago
p.(Ile127Thr) c.380T>C Exon 3 Missense Diabetes Heterozygous Not known 0 Paris
p.(Ile137Ser) c.410T>G Exon 3 Missense Diabetes Heterozygous Not known 0 Paris
p.? c.580–16_580–
14del
Intron 4 Intronic deletion Diabetes Heterozygous Not known 0.00001776 Paris
p.(Arg194Lys) c.581G>A Exon 5 Missense Diabetes Heterozygous Not known 0 Paris
p.(Pro201Leu) c.602C>T Exon 5 Missense HI Heterozygous Maternal 0 Paris
p.(Ala240Thr) c.718G>A Exon 5 Missense HI Heterozygous Maternal 0 Paris
p.(Met257Leu) c.769A>C Exon 5 Missense Diabetes Heterozygous Not known 0.000003976 Paris
p.(Met257Thr) c.770T>C Exon 5 Missense Diabetes Heterozygous Not known 0 Paris
p.(Phe270Cys) c.809T>G Exon 5 Missense Diabetes Heterozygous Not known 0 Paris
p.(His293Pro) c.878A>C Exon 6 Missense HI Heterozygous Paternal 0 Chicago
p.(Gly316Glu) c.947G>A Exon 6 Missense HI Heterozygous Paternal 0 Chicago
p.(Gly342Arg) c.1024G>A Exon 7 Missense Diabetes Heterozygous Not known 0.00001591 Paris









p.(Ile395Phe) c.1183A>T Exon 8 Missense NDM Heterozygous Not known 0.000007953 Chicago
p.(Thr413Ser) c.1238C>G Exon 8 Missense Diabetes Heterozygous Maternal 0 Exeter
p.(Asp424Gly) c.1271A>G Exon 9 Missense PNDM Homozygous Recessive 0 Paris
p.(Ile446Thr) c.1337T>C Exon 9 Missense Diabetes Heterozygous Not known 0.00001194 Paris
p.(Gly457Arg) c.1369G>A Exon 9 Missense Diabetes Heterozygous Affected
parent
0.00004598 Paris
p.(Arg504Cys) c.1510C>T Exon 10 Missense Diabetes Heterozygous Unaffected
parent
0.000007969 Paris
p.(Gly505Cys) c.1513G>T Exon 10 Missense HI Heterozygous Paternal 0 Paris
p.(Ala513Thr) c.1537G>A Exon 10 Missense Diabetes Heterozygous Unaffected
mother
0.00004601 Paris






p.(Arg521Gln) c.1562G>A Exon 10 Missense Diabetes Heterozygous Not known 0.00009556 Paris
p.(Val522Met) c.1564G>A Exon 10 Missense Diabetes Heterozygous Not known 0.000007078 Paris
p.(Ala537Thr) c.1609G>A Exon 10 Missense HI Heterozygous Paternal 0 Paris
p.(Val575Met) c.1723G>A Exon 12 Missense Diabetes Heterozygous Not known 0.00001591 Paris
p.(Phe613Leu) c.1837T>C Exon 13 Missense Diabetes Heterozygous Not known 0 Paris
(Continues)




position Position Mutation type Phenotype Zygosity Inheritance GnomAD MAF
Reporting
laboratory
p.? c.1924–44A>G Intron 13 Intronic
substitution
HI Heterozygous Paternal 0 Odense
p.(Cys656Phe) c.1967G>T Exon 14 Missense Diabetes Heterozygous Not known 0.000003984 Paris
p.(Arg702Cys) c.2104C>T Exon 15 Missense Diabetes Heterozygous Not known 0.00008768 Paris
p.? c.2116+61A>G Intron 15 Intronic
substitution
Diabetes Heterozygous Not known 0.00003187 Paris
p.(Gln731Glu) c.2191C>G Exon 16 Missense HI Heterozygous Not known 0.00001444 Paris








p.(Ser831Thr) c.2491T>A Exon 21 Missense Diabetes Heterozygous Not known 0 Paris
p.(Arg835His) c.2504G>A Exon 21 Missense Diabetes Heterozygous Not known 0.00002442 Paris
p.(Ile838Val) c.2512A>G Exon 21 Missense Diabetes Heterozygous Not known 0 Paris
p.(Val840Ala) c.2519T>C Exon 21 Missense Diabetes Heterozygous Not known 0 Paris
p.(Asn849Thr) c.2546A>C Exon 21 Missense Diabetes Heterozygous Not known 0 Paris




p.(Arg934Gln) c.2801G>A Intron 23 Missense HI Heterozygous Paternal 0.00001193 Paris
p.(Ala1002Thr) c.3004G>A Exon 25 Missense HI Homozygous, in cis
with VUS
Recessive 0.00003575 Paris









p.(Thr1038Asn) c.3113C>A Exon 25 Missense Diabetes Heterozygous Not known 0 Paris







p.? c.3561–19A>C Intron 28 Intronic
substitution
HI Heterozygous Not known 0 Chicago
p.(Asp1194Val) c.3581A>T Exon 29 Missense Diabetes Heterozygous Not known 0.00005303 Paris




p.(Phe1217Leu) c.3651C>G Exon 29 Missense TNDM Heterozygous Unaffected
parent
0 Paris












p.(Leu1241Arg) c.3722T>G Exon 30 Missense HI Heterozygous Paternal 0 Paris
p.(Glu1249Ala) c.3746A>C Exon 30 Missense HI Heterozygous Affected
mother
0 Paris
p.(Glu1253Gly) c.3758A>G Exon 31 Missense HI Heterozygous Maternal 0 Chicago
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